These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 30247524)

  • 21. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
    van Dijk E; van Werkhoven E; Asher R; Mooi JK; Espinoza D; van Essen HF; van Tinteren H; van Grieken NCT; Punt CJA; Tebbutt NC; Ylstra B
    Int J Cancer; 2022 Oct; 151(7):1166-1174. PubMed ID: 35489024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
    Weickhardt AJ; Williams DS; Lee CK; Chionh F; Simes J; Murone C; Wilson K; Parry MM; Asadi K; Scott AM; Punt CJ; Nagtegaal ID; Price TJ; Mariadason JM; Tebbutt NC
    Br J Cancer; 2015 Jun; 113(1):37-45. PubMed ID: 26125443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
    Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival.
    Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
    Clin Colorectal Cancer; 2018 Sep; 17(3):165-169. PubMed ID: 29576428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.
    Demircan NC; Dane F; Ozturk MA; Babacan NA; Besiroglu M; Kaya S; Ercelep O; Tanrikulu E; Halil S; Koca S; Alan O; Hasanov R; Yumuk PF
    J BUON; 2019; 24(4):1494-1500. PubMed ID: 31646797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
    Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
    Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
    Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
    Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
    Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
    Lim SH; Cho HJ; Kim KM; Lim HY; Kang WK; Lee J; Park YS; Kim HC; Kim ST
    Oncol Res; 2023; 31(6):855-866. PubMed ID: 37744267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
    Chionh F; Gebski V; Al-Obaidi SJ; Mooi JK; Bruhn MA; Lee CK; Chüeh AC; Williams DS; Weickhardt AJ; Wilson K; Scott AM; Simes J; Hardingham JE; Price TJ; Mariadason JM; Tebbutt NC
    Sci Rep; 2022 Jan; 12(1):1238. PubMed ID: 35075138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.